Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib Maleate in Myeloproliferative Neoplasms
NCT05153343Phase 2Completed
- Sponsor
- Zenitar
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of flonoltinib in myeloproliferative neoplasms (MPN), myelofibrosis (MF), polycythemia vera (PV) and 1 more (6 arms), sponsored by Zenitar. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 8 more. Started Dec 2021; status: completed.
02
Drugs
flonoltinib
03
Conditions
myeloproliferative neoplasms (MPN)myelofibrosis (MF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT05153343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153343.